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The tyrosine kinase inhibitor tyrphostin AG126 reduces renal
ischemia/reperfusion injury in the rat.
Background. We investigate the effects of tyrphostin AG126,
an inhibitor of tyrosine kinase activity, on the renal dysfunction
and injury caused by ischemia/reperfusion (I/R) of the kidney.
Methods. Tyrphostin AG126 (5 mg/kg intraperitoneally)
was administered to male Wistar rats 30 minutes prior to bilat-
eral renal ischemia for 45 minutes followed by reperfusion for
up to 48 hours. Biochemical markers of renal dysfunction and
injury were measured and renal sections assessed for renal
injury. Expression of inducible nitric oxide synthase (iNOS)
and cyclooxygenase-2 (COX-2) and formation of nitrotyrosine
and poly (ADP) ribose (PAR) were assessed using immunohis-
tochemistry. Rat proximal tubular cells (PTCs) were incubated
with interferon- (100 IU/mL), bacterial lipopolysaccharide
(10 g/mL), and with increasing concentrations of tyrphostin
AG126 (0.0001–1 mmol/L) for 24 hours. Nitric oxide produc-
tion was measured in both plasma from rats subjected to I/R
and in incubation medium from PTCs.
Results. After 6 hours of reperfusion, tyrphostin AG126 sig-
nificantly reduced the increase in serum and urinary indicators
of renal dysfunction and injury caused by I/R and reduced
histologic evidence of renal injury. Tyrphostin AG126 also
improved renal function (after 24 and 48 hours of reperfusion)
and reduced the histologic signs of renal injury (after 48 hours
of reperfusion). Tyrphostin AG126 reduced the expression of
iNOS and nitric oxide levels in both rat plasma and in PTC
cultures, as well as expression of COX-2. Tyrphostin AG126
also reduced nitrotyrosine and PAR formation, suggesting re-
duction of nitrosative stress and poly (ADP-ribose) polymerase
(PARP) activation, respectively.
Conclusion. Taken together, these results show that tyr-
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phostin AG126 significantly reduces the renal dysfunction and
injury caused by I/R of the kidney. We propose that inhibition
of tyrosine kinase activity may be useful against renal I/R
injury.
Despite significant advances in critical care medicine,
acute renal failure (ARF) remains a major clinical prob-
lem, producing considerable morbidity and mortality,
which has not decreased significantly over the last 50
years [1–3]. Renal ischemia, whether caused by shock
or during surgery or transplantation, is a major cause of
ARF, initiating a complex and interrelated sequence of
events, resulting in injury to, and eventual death of, renal
cells [3, 4]. The prognosis is complicated by the fact
that reperfusion, although essential for the survival of
ischemic renal tissue, causes additional damage (reperfu-
sion injury) [5, 6], which contributes to the renal dysfunc-
tion and injury associated with ischemia/reperfusion
(I/R) of the kidney [3–6]. Within the kidney, the proximal
tubule (PT) appears to be particularly susceptible to I/R
injury, leading to acute tubular necrosis (ATN), which
plays a pivotal part in the pathogenesis of ARF [4, 6].
Previous interventions against ARF have proved to be
largely negative and dialysis still remains the only effec-
tive therapy [1, 2]. The development of novel therapies
for the reduction of renal dysfunction and injury caused
by I/R has, therefore, been a topic of intense research
interest [1, 2].
Nitric oxide, generated by any one of the three iso-
forms of nitric oxide synthase (NOS) plays an important
role in renal function, both under normal and pathophys-
iologic conditions [7, 8]. Although nitric oxide appears
to play an important functional role within the PT, it
can also contribute to pathophysiology of this part of
the kidney [9, 10]. All three isoforms of NOS have been
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located in the kidney; the constitutive isoform [endothe-
lial NOS (eNOS) and neuronal NOS (nNOS)] isoforms
have been identified in the renal vasculature and macula
densa, respectively [7, 8] and inducible NOS (iNOS)
can be induced in the kidney by cytokines, bacterial
lipopolysaccharide (LPS) and during I/R [8–13], leading
to renal cell injury [14]. Furthermore, both cyclooxygen-
ase (COX)-1 and COX-2 are expressed in distinct but
important areas of the kidney [15, 16]; however, the role
of COX-2 induction in the development of renal I/R
injury still remains unclear [11, 17, 18]. Induction of
COX-2 results in an enhanced formation of metabolites
of arachidonic acid (e.g., vasodilator prostaglandins),
which exert proinflammatory effects [19], and elevated
plasma levels of certain prostaglandins have been docu-
mented in rats and patients with renal injury and disease
[20, 21]. Furthermore, it is now clear that the production
of reactive oxygen species (ROS) such as hydrogen per-
oxide, superoxide, and hydroxyl radicals contribute sig-
nificantly to the development of renal I/R injury (and
associated ARF) [5, 22]. Superoxide anions also react
with nitric oxide to form peroxynitrite [23], which causes
injury via oxidant injury and protein tyrosine nitration
[24]. Specifically in the kidney, peroxynitrite generation
has been implicated in the pathophysiology of both re-
nal I/R and hypoxia-reoxygenation injury, respectively
[11–14, 25–27]. Both ROS and peroxynitrite also cause
DNA damage during renal I/R [27, 28], leading to the
activation of the nuclear enzyme poly (ADP-ribose)
polymerase (PARP), depletion of NAD and adenosine
triphosphate (ATP) and ultimately cell death [29, 30].
Thus, various strategies that reduce the formation or
presence of ROS, such as the use of TEMPOL, TEM-
PONE, or desferrioxamine, have been shown to provide
beneficial actions against renal dysfunction and injury
caused by I/R of the kidney [31, 32].
Phosphorylation of proteins on tyrosine residues by
protein tyrosine kinases plays an important role in the
regulation of cell proliferation, cell differentiation, and
cellular signaling processes [33, 34]. The receptor tyro-
sine kinases participate in transmembrane signaling,
whereas the intracellular tyrosine kinases mediate signal
transduction to the nucleus [33]. Enhanced tyrosine ki-
nase activity has been implicated in the pathophysiology
of many diseases states, including cancer, atherosclerosis,
and psoriasis [35, 36], and several protein kinase inhibi-
tors have been developed as novel therapeutics for the
therapy of systemic inflammation, shock, and organ in-
jury [37]. Many previous strategies aimed at reducing
renal I/R injury have been limited to targeting a single
mediator [11–13, 29–32]. In contrast, tyrosine kinase in-
hibitors act directly on cells rather than individual media-
tors [e.g., by reducing the activation of the transcription
factor nuclear factor (NF)-B] and thereby, expression
of iNOS and COX-2 and the formation and/or effects
of proinflammatory cytokines [e.g., tumor necrosis factor
(TNF)- and interleukin (IL)-1] [38–40]. Tyrosine ki-
nase inhibitors have therefore provided a promising ap-
proach for the modulation of diseases with abnormalities
in protein kinase signaling pathways such as renal cell
carcinoma [41]. A particular family of tyrosine kinase
inhibitors, the tyrphostins, which are derivatives of ben-
zylidene malononitrile, have been described as potential
antiproliferative agents [42–44]. The expression of iNOS
caused by inflammatory stimuli in cultured cells involves
the phosphorylation of tyrosine residues in proteins and
is prevented by the tyrosine kinase inhibitors genistein,
erbstatin and tyrphostin AG126 [45–48]. The expression
of COX-2 by endotoxin or proinflammatory cytokines
is also mediated by tyrosine kinases [47] and can be
inhibited by tyrphostin AG126 and erbstatin [49, 50].
The effect of inhibition of tyrosine kinase activity on
renal I/R injury is not known. We propose here that
inhibition of the activity of protein tyrosine kinases may
represent a novel approach for the therapy of renal I/R
injury and investigate the effects of tyrosine kinase inhib-
itor tyrphostin AG126 on the renal dysfunction and in-
jury caused by I/R of the kidney of the rat. We also
hypothesize here that tyrphostin AG126 reduces the acti-
vation of the transcription factor NF-B, thereby reduc-
ing the expression of proinflammatory genes. We have
therefore investigated the effects of tyrphostin AG126
on the expression of two such proinflammatory genes
(iNOS and COX-2). Finally, we have investigated the
effects of tyrphostin AG126 on the formation of nitric
oxide and nitrotyrosine and subsequent activation of
PARP, all of which are implicated in the development
of renal I/R injury.
METHODS
Renal ischemia/reperfusion (short-term model)
In vivo studies were carried out using 60 male Wistar
rats (Tuck, Rayleigh, Essex, UK) weighing 220 to 310 g.
Rats received a standard diet and water ad libitum and
were cared for in accordance with both the Home Office
Guidance in the Operation of the Animals (Scientific Pro-
cedures) Act of 1986, published by Her Majesty’s Statio-
nery Office, London, U.K. and the Guiding Principles in
the Care and Use of Animals published by the American
Physiological Society. Rats were subjected to bilateral
renal ischemia for 45 minutes followed by reperfusion
for 6 hours as described previously [30, 31]. Upon com-
pletion of surgical procedures, rats were randomly allo-
cated into the following five groups: (1) I/R  saline
group, in which rats were administered 2 mL/kg saline
intraperitoneally 30 minutes prior to renal I/R (45 min-
utes renal ischemia followed by reperfusion for 6 hours)
(N  12); (2) I/R  vehicle group, which was the same
as I/R saline group, but rats were administered vehicle
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for tyrphostin AG126 [2 mL/kg 50% (vol/vol) dimethyl
sulfoxide (DMSO) in 0.9% (vol/vol) saline, intraperito-
neally] 30 minutes prior to I/R (N  12); (3) I/R 
tyrphostin AG126 group, in which rats were adminis-
tered tyrphostin AG126 (5 mg/kg, intraperitoneally) 30
minutes prior to I/R (N  12); (4) sham  saline group,
in which rats were administered 2 mL/kg saline intraperi-
toneally 30 minutes prior to undergoing identical surgical
procedures as the above groups except for renal I/R, and
were maintained under anesthesia for the duration of
the experiment (45 minutes  6 hours, N  12); and (5)
sham  tyrphostin AG126 group; which was identical
to sham-operated rats except for the administration of
tyrphostin AG126 (5 mg/kg, intraperitoneally) 30 min-
utes prior to undergoing identical surgical procedures as
the above groups except for renal I/R, and were main-
tained under anesthesia for the duration of the experi-
ment (45 minutes  6 hours, N  12). All rats received
an infusion of saline (2 mL/kg/hour) throughout I/R.
Renal ischemia/reperfusion injury (long-term model)
To assess the effects of tyrphostin AG126 administra-
tion on renal function and injury in the later stages of
ischemic ARF, further studies were performed using 25
male Wistar rats (Charles River, Milan, Italy) weighing
200 to 260 g. Rats were allowed access to food and water
ad libitum and were cared for in compliance with Italian
regulations on protection of animals used for experimen-
tal and other scientific purposes (DM 116192), as well
as with the European Economic Community regulations
(OJ of EC L358/1, December 18, 1986).
Rats were subjected to bilateral renal ischemia for 45
minutes followed by reperfusion for up to 48 hours as
described previously [51]. Rats were anesthetised using
chloral hydrate (400 mg/kg, intraperitoneally) and core
body temperature maintained at 37C using a homeo-
othermic blanket. Rats were then divided into the follow-
ing four groups: (1) I/R  saline group, in which rats
were subjected to renal ischemia (45 minutes) followed
by reperfusion for 48 hours and were administered 2 mL/
kg saline, intraperitoneal bolus 30 minutes before sham
operation and after 12 hours (N 10); (2) I/R  vehicle
group, in which rats were subjected to renal ischemia
(45 minutes) followed by reperfusion for 48 hours and
were administered 2 mL/kg 50% (vol/vol) DMSO/saline
(vehicle for tyrphostin AG126), intraperitoneally 30 min-
utes before sham operation and after 12 hours (N  5);
(3) I/R  tyrphostin AG126 group, in which rats were
subjected to renal ischemia (45 minutes) followed by
reperfusion for 48 hours; rats were administered tyrphos-
tin AG126 (5 mg/kg intraperitoneal bolus) 30 minutes
prior to commencement of I/R and after 12 hours of
reperfusion (N  5); and (4) sham  saline group, in
which rats were subjected to identical surgical proce-
dures except for renal I/R (N  5).
After performing a flank incision, rats belonging to
the I/R groups were subjected to bilateral renal ischemia
for 45 minutes during which the renal arteries and veins
were occluded using microaneurysm clamps. After the
renal clamps were removed, the kidneys were observed
for a further 5 minutes to ensure reflow, after which 1 mL
saline at 37C was injected into the abdomen and the
incision was sutured in two layers. Rats were then re-
turned to their cages where they were allowed to recover
from anesthesia and observed for 48 hours. Sham-oper-
ated rats underwent identical surgical procedures to I/R
rats except that microaneurysm clamps were not applied.
The time course and doses of tyrphostin AG126 used in
this study were based on those previously shown by us,
and others, to provide beneficial actions against endo-
toxic shock (which involves an element of renal I/R in-
jury) or inflammation in the rat [50, 52–56].
Measurement of biochemical parameters
At the end of the reperfusion period (short-term
model) or after 24 and 48 hours of reperfusion (long-
term model), blood samples were collected via the ca-
rotid artery or tail vein into tubes containing serum gel.
The samples were centrifuged (6000 rpm for 3 minutes)
to separate serum from which biochemical parameters
were measured (Vetlab Services, Sussex, UK; or by DB,
University of Teramo, Italy). Serum creatinine concen-
trations were used as indicators of glomerular function
[30, 31]. Aspartate aminotransferase (AST), an enzyme
located in the PT, was used as an indicator of reperfusion
injury [13, 31, 57]. Urine samples were collected through-
out the reperfusion period and the volume of urine pro-
duced recorded. Urine concentrations of Na were mea-
sured (Vetlab Services) at the end of the reperfusion
period and used in conjunction with serum Na concen-
trations to estimate fractional excretion of sodium (FENa)
using standard formulas, and which was used as an indi-
cator of tubular function [30, 31]. Concentrations of uri-
nary N-acetyl--d-glucosaminidase (NAG), a specific in-
dicator of tubular damage [13, 31], was also measured
(Clı´nica Me´dica e´ Diagno´stico Dr. Joaquim Chaves, Lis-
bon, Portugal) and used as a marker of tubular injury.
Histologic evaluation
Renal sections were prepared as described previously
and used for the assessment of renal I/R injury [13, 31].
Briefly, 100 intersections were examined for each kidney
and a score from 0 to 3 was given for each tubular profile
involving an intersection: 0, normal histology; 1, tubular
cell swelling, brush border loss, nuclear condensation,
with up to one third of tubular profile showing nuclear
loss; 2, as for score 1, but greater than one third and less
than two thirds of tubular profile shows nuclear loss; and
3, greater than two thirds of tubular profile shows nuclear
Chatterjee et al: Tyrphostin AG126 reduces renal I/R injury1608
loss. The total score for each kidney was calculated by
addition of all 100 scores with a maximum score of 300.
Immunohistochemical localisation of iNOS, COX-2,
nitrotyrosine, and PAR
Immunohistochemical localisation of iNOS, COX-2,
nitrotyrosine (indicative of peroxynitrite formation and/or
nitrosative stress, see Discussion section), and poly
(ADP-ribose) (PAR) (indicative of PARP activation,
see Discussion section) in kidney sections was performed
as previously described [11–13, 29–32]. Kidneys were
fixed in 10% formalin buffered using phosphate-buffered
saline (PBS) (0.01 mol/L, pH 7.4) and 8 m sections
were prepared from paraffin-embedded tissues. After
deparaffinization, endogenous peroxidase was quenched
with 0.3% (vol/vol) hydrogen peroxide in 60% (vol/vol)
methanol for 30 minutes. Sections were then permeabil-
ized with 0.1% (vol/vol) Triton X-100 in PBS for 20
minutes and nonspecific adsorption was minimized by
incubation in 2% (wt/vol) normal goat serum in PBS for
20 minutes. Endogenous biotin or avidin binding sites
were blocked by sequential incubation for 15 minutes
with avidin and biotin (DBA, Milan, Italy). Sections
were then incubated overnight at 4C with primary anti-
iNOS, anti-COX-2, anti-PAR or anti-nitrotyrosine anti-
body [1:500 (vol/vol) in PBS] (DBA) or with control
solutions which included incubation with buffer alone
or nonspecific purified rabbit IgG (DBA). Specific label-
ing of antigen-antibody complex was visualized using a
biotin-conjugated goat antirabbit IgG (DBA) and avi-
din-biotin peroxidase complex (DBA) immunoperoxi-
dase technique using chromogen diaminobenzidine.
Isolation and culture of rat proximal tubular cells
Rat proximal tubular cells (PTCs) were isolated from
kidneys obtained from 12 male Wistar rats (250 to 350 g)
using collagenase digestion, differential sieving and Per-
coll density centrifugation as described previously [31].
Primary cultures of PTCs were cultured in minimum
essential medium (MEM) containing 10% (vol/vol) fetal
calf serum (FCS) in a humidified 5% CO2/95% air atmo-
sphere at 37C and medium was changed every 48 hours
until the cells reached confluence.
In vitro experimental design
Confluent primary cultures of PTCs were incubated
with 100 IU/mL interferon- (IFN-) and 10 g/mL LPS
in combination for 24 hours in the absence or presence
of increasing concentrations of tyrphostin AG126
(0.0001 to 1 mmol/L). The range of tyrphostin AG126
concentrations used was determined from previous stud-
ies, which have shown tyrphostin AG126 to effectively
inhibit nitric oxide production by J774.2 macrophages
incubated with LPS for 24 hours [50]. Tyrphostin AG126
was added to incubation medium (MEM) 10 minutes
before the addition of IFN- and LPS to provide final
concentrations ranging from 0.0001 to 1 mmol/L. Upon
completion of incubations (24 hours after the addition
of IFN-/LPS), nitric oxide levels in incubation medium
were measured as nitrite (NO2)/nitrate (NO3) after con-
version of nitrate to NO2 using NO3 reductase as de-
scribed below and previously [12, 13].
Measurement of nitrite/nitrate concentrations
Concentrations of NO2/NO3, the primary oxidation
products of nitric oxide subsequent to reaction with oxy-
gen, were measured and used as an indicator of nitric
oxide synthesis. NO2/NO3 levels in rat plasma and incu-
bation medium from PTCs were measured as previously
described after enzymatic conversion of NO3 to NO2
using nitrate reductase [12, 13].
Statistical analysis
All values described in the text and figures are ex-
pressed as mean	 standard error of the mean (SEM) for
N observations. Each data point represents biochemical
measurements obtained from 12 separate rats. For histo-
logic scoring, each data point represents analysis of kid-
neys taken from six individual rats. For immunohisto-
chemical analysis, the figures shown are representative
of at least six experiments performed on different experi-
mental days. For in vitro studies involving PTCs, mea-
surements were taken from cultures obtained from 12
separate isolations using both kidneys from 12 separate
rats. For the determination of NO2/NO3 levels in incuba-
tion medium, experiments were performed in triplicate.
Statistical analysis was carried out using GraphPad Prism
3.02/Instat 1.1 (GraphPad Software, San Diego, CA,
USA). Data were analyzed using one-way analysis of
variance (ANOVA) followed by Dunnett’s post hoc test
and a P value of less than 0.05 was considered to be
significant.
Materials
Unless otherwise stated, all compounds used in this
study were purchased from Sigma-Aldrich Company,
Ltd. (Poole, Dorset, UK). All stock solutions were pre-
pared using nonpyrogenic saline [0.9% (wt/vol) NaCl;
Baxter Healthcare Ltd., Thetford, Norfolk, UK]. LPS
was obtained from Escherichia coli serotype 0.127:B8
(Sigma Aldrich Company).
RESULTS
The mean 	 SEM for the weights of the rats used in
the short-term study was 252 	 5 g (N  60) and for
the long-term study was 220	 2 g (N 25). On compari-
son with sham  saline rats, renal I/R produced signifi-
cant increases in serum, urinary, and histologic markers
of renal dysfunction and injury as described in detail
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Fig. 1. Effect of tyrphostin AG126 (Tyr AG126) on glomerular func-
tion. (A ) Serum creatinine levels and (B ) creatinine clearance were
measured subsequent to sham operation (sham  saline) or renal
ischemia/reperfusion (I/R) (I/R  saline) in the absence or presence
of tyrphostin AG126 (5 mg/kg administered intraperitoneally 30 min-
utes prior to I/R). A separate group of rats received vehicle for tyrphos-
tin AG126 [50% (vol/vol) dimethyl sulfoxide (DMSO)/saline] 30 min-
utes prior to I/R (I/R  vehicle). *P 
 0.05 vs. I/R  saline group,
P 
 0.05 vs. sham  saline group.
below (Figs. 1 to 4). When compared to rats used as
shams, renal I/R [in the presence or absence of tyrphostin
AG126 or its vehicle [50% (vol/vol) DMSO/50% (vol/
vol) saline] did not have a significant effect on urine flow
(0.015 	 0.002 mL/min, N  60).
Effect of tyrphostin AG126 on renal dysfunction
caused by I/R
Rats that underwent renal I/R exhibited significant
increases in the serum concentrations of creatinine com-
pared to sham-operated rats (Fig. 1A), suggesting a sig-
nificant degree of glomerular dysfunction. Compared to
rats subjected to I/R only (I/R  saline or I/R  vehicle
groups), administration of tyrphostin AG126 to rats prior
Fig. 2. Effect of tyrphostin AG126 (Tyr AG126) on tubular function
and injury. (A ) Fractional excretion of sodium (FENa) and (B ) urinary
levels of N-acetyl--d-glucosaminidase (NAG) were measured as re-
spective markers of tubular function and injury, subsequent to sham-
operation (sham  saline) or renal ischemia/reperfusion (I/R) (I/R 
saline) in the absence or presence of tyrphostin AG126 (5 mg/kg admin-
istered intraperitoneally 30 minutes prior to I/R). A separate group of
rats received vehicle for tyrphostin AG126 [50% (vol/vol) dimethyl
sulfoxide (DMSO)/saline] 30 minutes prior to I/R (I/R vehicle). *P

0.05 vs. I/R  saline group, P 
 0.05 vs. sham  saline group.
to renal I/R produced a modest, but significant reduction
in the increase in serum levels of creatinine caused by
renal I/R (Fig. 1A). In order to discount the possibility
of a rapid increase in serum creatinine levels due to
increased release of creatinine from muscle during I/R,
creatinine clearance was also measured (Fig. 1B). Rats
subjected to renal I/R demonstrated a significant reduc-
tion in creatinine clearance compared to sham-operated
rats (Fig. 1B), suggesting significant glomerular dysfunc-
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Fig. 3. Effect of tyrphostin AG126 (Tyr AG126) on reperfusion injury
and histologic scoring of renal injury. (A ) Serum levels of aspartate
aminotransferase (AST) were measured as an indicator of reperfusion
injury and (B) renal sections were scored for characteristic histologic
signs of renal injury subsequent to sham operation (sham  saline) or
renal ischemia/reperfusion (I/R) (I/R  saline) in the absence or pres-
ence of tyrphostin AG126 (5 mg/kg administered intraperitoneally 30
minutes prior to I/R). A separate group of rats received vehicle for
tyrphostin AG126 [50% (vol/vol) dimethyl sulfoxide (DMSO)/saline]
30 minutes prior to I/R (I/R  vehicle). *P 
 0.05 vs. I/R  saline
group, P 
 0.05 vs. sham  saline group.
tion. Compared to rats subjected to I/R only, administra-
tion of tyrphostin AG126 produced a modest, but sig-
nificant improvement in creatinine clearance (Fig. 1B).
Administration of vehicle for tyrphostin AG126 to
rats (I/R  vehicle group) did not have a significant
effect on the increased serum levels of creatinine or
reduction in creatinine clearance associated with renal
I/R (Fig. 1). Administration of tyrphostin AG126 to
sham-operated rats (sham  tyrphostin AG126 group)
did not have any effect on serum creatinine levels or
creatinine clearance when comparison with sham-oper-
Fig. 4. Effect of tyrphostin AG126 (Tyr AG126) on the course of renal
ischemia/reperfusion (I/R) injury. (A ) Serum creatinine levels were
measured 24 and 48 hours after renal ischemia in rats subjected to I/R
and which were administered either saline [()  I/R  saline] or 5
mg/kg tyrphostin AG126 [() I/R  Tyr AG126] 30 minutes prior
to ischemia and after 12 hours of reperfusion. Data represent mean 	
SEM for N observations. *P 
 0.05 vs. I/R  saline group. Histologic
examination of kidney sections prepared from rats subjected to ischemia
followed by reperfusion for 48 hours and treated with saline (B ) dis-
played more severe renal injury than rats subjected to I/R but which
were administered tyrphostin AG126 (C ). Hemotoxylin and eosin, orig-
inal magnification 125, figures are representative of at least three
experiments performed on different days.
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ated rats administered saline only (sham saline group)
(Fig. 1).
Effect of tyrphostin AG126 on tubular dysfunction
and injury caused by renal I/R
Renal I/R produced significant increases in FENa (Fig.
2A) and urinary levels of NAG (Fig. 2B), suggesting a
marked increase in tubular dysfunction and injury, respec-
tively. On comparison with FENa measured in rats sub-
jected to I/R-only, administration of tyrphostin AG126
produced a significant reduction in the increase in FENa
associated with renal I/R (Fig. 2A), suggesting improve-
ment in tubular function. Administration of tyrphostin
AG126 also significantly reduced the increase in urinary
NAG levels caused by renal I/R (Fig. 2B), suggesting
reduction of tubular injury. Administration of the vehicle
for tyrphostin AG126 to rats did not have a significant
effect on the increase in FENa (Fig. 2A) and administration
of tyrphostin AG126 to sham-operated rats did not have
any effect on FENa when compared with sham-operated
rats administered saline only (Fig. 2A).
Effect of tyrphostin AG126 on reperfusion injury
caused by renal I/R
On comparison with values obtained from sham 
saline rats, renal I/R produced significant increases in
serum concentrations of AST (suggesting significant re-
perfusion injury) (Fig. 3A). Administration of tyrphostin
AG126 prior to I/R caused a significant reduction in the
increase in serum AST levels caused by renal I/R (Fig.
3A). Administration of the vehicle for tyrphostin AG126
to rats did not have a significant effect on the increase
in AST levels associated with renal I/R (Fig. 3A) and
administration of tyrphostin AG126 to sham-operated
rats did not have any effect on serum AST levels on
comparison with sham-operated rats administered saline
only (Fig. 3A).
Effects of tyrphostin AG126 on scoring
of renal histopathology
On comparison with the total severity score measured
from kidneys obtained from sham  saline rats, renal
I/R produced a significant increase in total severity score
(Fig. 3B). Administration of tyrphostin AG126 to rats
subjected to I/R only (I/R  tyrphostin AG126 group)
significantly reduced the increase in total severity score
associated with renal I/R when compared to that ob-
tained from rats subjected to renal I/R only (I/R saline
group) (Fig. 3B).
Effect of tyrphostin AG126 on the course
of renal I/R injury
In the long-term model of ischemic ARF, renal func-
tion (assessed by serum creatinine levels) was signifi-
cantly improved after administration of tyrphostin AG126
to rats subjected to renal ischemia followed by reperfu-
sion for 24 and 48 hours (Fig. 4A). Histologic examina-
tion of kidney sections prepared from rats subjected to
ischemia followed by reperfusion for 48 hours and
treated with vehicle for tyrphostin AG126 (I/R vehicle
group) (Fig. 4B) demonstrated greater renal injury than
rats subjected to I/R but which were administered tyrphos-
tin AG126 (I/R  tyrphostin AG126 group) (Fig. 4C).
Effects of tyrphostin AG126 on iNOS expression and
plasma nitric oxide levels
When compared to kidney sections obtained from
sham saline rats (Fig. 5A), immunohistochemical anal-
ysis of sections obtained from rats subjected to renal I/R
only revealed positive staining for iNOS (Fig. 5B). In
contrast, reduced staining was observed in the kidney
sections obtained from rats administered tyrphostin
AG126 prior to renal I/R (Fig. 5C). Administration of
(1) tyrphostin to sham-operated rats or (2) vehicle for
tyrphostin AG126 to rats subjected to I/R did not have
a significant effect on the expression of iNOS caused by
renal I/R (data not shown).
Renal I/R resulted in a significant increase in the
plasma levels of NO2/NO3 (an indicator of the formation
of nitric oxide) on comparison with values obtained from
the plasma of sham  saline rats (Fig. 5D). Increased
plasma NO2/NO3 levels caused by renal I/R were reduced
by administration of tyrphostin AG126 to rats prior to
renal I/R (Fig. 5D). Administration of the vehicle for
tyrphostin AG126 to rats did not have a significant effect
on the increased plasma levels of NO2/NO3 associated
with renal I/R (Fig. 5D) and administration of tyrphostin
AG126 to sham-operated rats did not have any effect
on plasma NO2/NO3 levels when compared with sham-
operated rats administered saline only (Fig. 5D).
Effect of tyrphostin AG126 on nitric oxide production
by rat PTC cultures
Incubation of primary cultures of rat PTCs with IFN-
and LPS in combination for 24 hours produced a signifi-
cant increase in nitric oxide production as determined
by measurement of NO2/NO3 levels (Fig. 5E). Incubation
of PTCs with IFN- and LPS in the presence of increas-
ing concentrations of tyrphostin AG126 (0.0001 to 1
mmol/L) resulted in a significant, concentration-depen-
dent inhibition of nitric oxide production (Fig. 5E).
Effects of tyrphostin AG126 on COX-2 expression
When compared to kidney sections obtained from sham-
operated rats (Fig. 6A), immunohistochemical analysis
of sections obtained from rats subjected to renal I/R
revealed positive staining for COX-2 (Fig. 6B). In con-
trast, reduced staining for COX-2 was observed in the
kidney sections obtained from rats administered tyrphos-
tin AG126 prior to renal I/R (Fig. 6C). Administration
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Fig. 5. Effect of tyrphostin AG126 (Tyr AG126) on inducible nitric oxide synthase (iNOS) expression and nitric oxide production during renal
ischemia/reperfusion (I/R). Immunohistochemical localization of iNOS expression in rat kidney sections incubated overnight with primary antibody
directed against iNOS [1:500 dilution with phosphate-buffered saline (PBS)] in (A ) sham  saline group and (B ) I/R saline group. In comparison,
the iNOS expression in kidneys from rats treated with tyrphostin AG126 (5 mg/kg intraperitoneally administered 30 minutes prior to I/R) was
markedly reduced (C ). Original magnification, 125/150, figures are representative of at least 3 experiments performed on different experimental
days. (D ) Effect of tyrphostin AG126 (5 mg/kg administered intraperitoneally 30 minutes prior to I/R) on plasma NO2/NO3 levels subsequent to
sham operation (sham  saline) or renal I/R (I/R  saline). A separate group of rats received vehicle for tyrphostin AG126 [50% (vol/vol)
dimethyl sulfoxide (DMSO)/saline] 30 minutes prior to I/R (I/R  vehicle). *P 
 0.05 vs. I/R  saline group, P 
 0.05 vs. sham  saline group.
(E ) Primary cultures of rat proximal tubular (PT) cells were incubated with incubation medium only (untreated) or with 1 mmol/L tyrphostin
AG126 only (Tyr AG126 only) or a combination of interferon- (IFN-) (100 IU/mL) and lipopolysaccharide (LPS) (10 g/mL) (cytokine only)
for 24 hours. PT cells were also incubated with IFN- and LPS in the presence of increasing concentrations of tyrphostin AG126 (0.0001 to 1
mmol/L). After 24 hours, levels of NO2/NO3 were measured in the incubation medium. *P 
 0.05 vs. CK only group, P 
 0.05 vs. untreated
group.
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Fig. 6. Effect of tyrphostin AG126 (Tyr AG126) on cyclooxygen-
ase-2 (COX-2) expression during renal ischemia/reperfusion (I/R). Im-
munohistochemical localization of the expression of COX-2 in rat kid-
ney sections incubated overnight with primary antibody directed against
COX-2 [1:500 dilution with phosphate-buffered saline (PBS)] in (A )
sham saline group and (B ) I/R saline group. In comparison, COX-2
expression in kidneys from rats treated with tyrphostin AG126 (5 mg/kg
intraperitoneally administered 30 minutes prior to I/R) was markedly
reduced (C ). Original magnification, 125, figures are representative
of at least three experiments performed on different experimental days.
of tyrphostin AG126 to sham-operated rats or its vehicle
to rats subjected to I/R did not have a significant effect
on the expression of COX-2 caused by renal I/R (data
not shown).
Effect of tyrphostin AG126 on PAR formation during
renal I/R
Formation of PAR was used as an indicator of the
activity of the nuclear enzyme PARP as previously de-
scribed [30] and, therefore, as an indicator of ROS for-
mation and oxidative stress [29–32]. In comparison to
renal sections obtained from sham-operated rats that
were administered saline only (Fig. 7A), immunohisto-
chemical analysis of renal sections obtained from rats
subjected to renal I/R revealed positive staining for PAR
(Fig. 7B). In contrast, substantially reduced staining was
observed in the kidney sections obtained from rats, which
were administered tyrphostin AG126 (Fig. 7C). Admin-
istration of (1) tyrphostin AG126 to sham-operated rats
or (2) vehicle for tyrphostin AG126 to rats subjected to
I/R did not have a significant effect on the formation of
PAR caused by renal I/R (data not shown).
Effect of tyrphostin AG126 on nitrotyrosine formation
during renal I/R
The formation of nitrotyrosine was used as an indica-
tor of nitrosative stress [11–13, 31, 32]. In comparison
to renal sections obtained from sham-operated rats that
were administered saline only (Fig. 8A), immunohisto-
chemical analysis of renal sections obtained from rats
subjected to renal I/R revealed positive staining for nitro-
tyrosine (Fig. 8B). In contrast, substantially reduced
staining was observed in the kidney sections obtained
from rats that were administered tyrphostin AG126 prior
to renal I/R (Fig. 8C). Administration of tyrphostin
AG126 to sham-operated rats or its vehicle to rats sub-
jected to I/R did not have a significant effect on nitrotyro-
sine formation (data not shown).
DISCUSSION
In the present study, we have shown that renal I/R of
the rat kidney results in a reduction in renal function as
was demonstrated by increased serum levels of creati-
nine. This glomerular dysfunction correlated with in-
creased FENa indicating dysfunction of the PT. Tubular
injury was also confirmed by an increase in NAG enzy-
muria and increased serum levels of AST confirmed re-
perfusion injury caused by renal I/R. All these data,
together with increased expression of iNOS and COX-2,
as well as peroxynitrite formation and PARP activation,
confirmed a well-known pattern of renal dysfunction and
injury associated with I/R of the kidney [6, 58, 59] and
are in agreement with the notion that renal I/R causes
both glomerular and tubular dysfunction [60]. Character-
istic histologic signs of tubular injury were also observed
in kidneys subsequent to renal I/R, in keeping with the
observation that the S3 segment of the PT is particularly
susceptible to renal I/R injury [61].
The main findings of the current study can be summa-
Fig. 7. Effect of tyrphostin AG126 (Tyr AG126) on nitrotyrosine for-
mation during renal ischemia/reperfusion (I/R). Immunohistochemical
localization of nitrotyrosine as an indicator of peroxynitrite formation
and/or nitrosative stress (see Discussion section) in rat kidney sections
incubated overnight with 1:500 dilution of primary antibody directed
against nitrotyrosine in (A ) sham  saline group and (B ) I/R  saline
group. In comparison, the nitrotyrosine immunoreactivity of kidneys
from rats treated with tyrphostin AG126 (5 mg/kg administered intra-
peritoneally 30 minutes prior to renal I/R) was markedly reduced (C ).
Original magnification,150, figures are representative of at least three
experiments performed on different experimental days.
Fig. 8. Effect of tyrphostin AG126 (Tyr AG126) on poly (ADP-ribose)
(PAR) formation during renal ischemia/reperfusion (I/R). Immunohis-
tochemical localization of PAR formation as an indicator of poly (ADP-
ribose) polymerase (PARP) activation in rat kidney sections incubated
overnight with primary antibody directed against PAR (1:500 dilution)
in (A ) sham saline group and (B ) I/R saline group. In comparison,
the PAR immunoreactivity of kidneys from rats treated with tyrphostin
AG126 (5 mg/kg administered intraperitoneally 30 minutes prior to
renal I/R) was markedly reduced (C ). Original magnification, 125,
figures are representative of at least three experiments performed on
different experimental days.
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rized as follows: (1) tyrphostin AG126 reduces the devel-
opment glomerular and tubular dysfunction caused by
renal I/R (serum creatinine levels, FENa), (2) tyrphostin
AG126 reduces tubular and reperfusion injury (urinary
NAG, AST) caused by renal I/R and the histologic evi-
dence of renal injury, (3) tyrphostin AG126 reduces
nitric oxide production subsequent to iNOS expression
caused by renal I/R (as determined using immunohisto-
chemistry), (4) tyrphostin AG126 reduces immunohisto-
chemical evidence for the expression of COX-2, (5) tyr-
phostin AG126 reduced the formation of nitrotyrosine
during renal I/R (indicating attenuation of peroxynitrite
production and/or nitrosative stress, see below), and (6)
tyrphostin AG126 reduced PAR formation (suggesting
attenuation of PARP activation, see below). All of these
findings support the view that tyrphostin AG126 attenu-
ates the degree of renal dysfunction and injury caused
by I/R of the kidney of the rat. The effects of tyrphostin
AG126 on renal dysfunction and injury were also investi-
gated in a longer-term model of ARF in which renal
function was assessed after 24 and 48 hours after isch-
emia. The data obtained indicate that administration of
tyrphostin AG126 can improve renal function at the later
stages of reperfusion following ischemia, which was re-
flected by a marked reduction in the histologic evidence
of renal injury after 48 hours of reperfusion.
What, then, are the mechanisms by which tyrphostin
AG126 protects the kidney against I/R? Tyrphostin
AG126, a derivative of benzylidene malononitrile, is a
potent inhibitor of protein tyrosine kinases in vitro and
in vivo [35, 42], which (among other effects) reduce the
expression of iNOS and COX-2 in models of endotoxic
and Gram-positive shock (which contains an element of
renal ischemia and dysfunction) [38, 39, 50]. In this study,
tyrphostin AG126 was able to markedly reduce the ex-
pression of iNOS caused by renal I/R and subsequently,
nitric oxide levels in vivo; an effect which was reflected
by the ability of tyrphostin AG126 to significantly reduce
nitric oxide production by rat PTCs in a dose-dependent
manner subsequent to the induction of iNOS by LPS/
IFN-. There is now good evidence that nitric oxide,
derived from NOS, plays an important role in renal func-
tion, both under normal and pathophysiologic conditions
[7, 8] and that high levels of nitric oxide produced by
iNOS are implicated in the renal dysfunction/injury asso-
ciated with either renal I/R [10–14, 26, 27, 62–64] or
during endotoxic and hemorrhagic shock [65, 66]. Sev-
eral in vivo and in vitro investigations have demonstrated
that inhibition of iNOS expression (e.g., using inhibitors
of NF-B activation), iNOS activity (e.g., using inhibitors
of iNOS activity), absence of iNOS itself (using iNOS
knockout mice), or scavenging of nitric oxide (e.g., using
hemoglobin) can ameliorate or prevent nitric oxide–
mediated renal injury [11–13, 25, 64–70] suggesting that
nitric oxide, generated by iNOS, contributes to renal I/R
injury. Thus, the inhibition of the expression of iNOS
and subsequent reduced levels of nitric oxide contribute
to the beneficial actions of tyrphostin AG126 against
renal I/R injury.
Here we also demonstrate that the increase in the
expression of COX-2 caused by renal I/R is abolished
in the kidneys of rats treated with tyrphostin AG126.
The promoter region of the murine and human COX-2
gene contains binding sites for NF-B [71, 72]. The ex-
pression of the COX-2 gene is caused by oxidant stress
[73], and ROS cause the activation of NF-B [74], sug-
gesting that NF-B is one of the transcription factors
involved. There is good evidence that an enhanced for-
mation of prostanoids following the induction of COX-2
contributes to the pathophysiology of associated with
I/R and inflammation [75, 76].
We report here that administration of tyrphostin
AG126 markedly reduced the expression of both iNOS
and COX-2 protein in kidneys obtained from rats sub-
jected to I/R. These findings are in keeping with studies
demonstrating that tyrphostin AG126 can reduce the
expression of iNOS and COX-2 genes in shock and in-
flammation [38–40, 48–50, 55–57, 77]. We hypothesize
here that tyrphostin AG126 mediates this effect via inhi-
bition of the expression of NF-B. There is now good
evidence that certain protein tyrosine kinases play a piv-
otal role in the activation of NF-B [78]. NF-B is a
member of a family of dimers belonging to the Rel/
NF-B family of polypeptides and the most frequently
observed form of NF-B is a dimer composed of two
DNA-binding proteins, namely NF-B (or p50) and
RelA (or p65), although other dimeric combinations also
exist [79]. Our hypothesis is supported by evidence ob-
tained from in vitro studies this laboratory and by others,
demonstrating that tyrphostin AG126 inhibits expression
of iNOS and COX-2 in macrophages and pulmonary
epithelial cells, respectively, via inhibition of the activa-
tion of NF-B [48, 50].
In this study, renal I/R caused an increase in the immu-
nologic evidence of the generation of peroxynitrite,
which was identified as increased nitration of proteins.
Generation of peroxynitrite causes renal injury via direct
oxidant injury and protein tyrosine nitration [24]. Nitro-
tyrosine formation, along with its detection using immu-
nohistochemical staining, was initially proposed as a rela-
tively specific marker for the detection or “footprint” of
the endogenous formation of peroxynitrite [80] although
there is more recent evidence that certain other reactions
can also induce tyrosine nitration (e.g., the reaction of
nitrite with hypochlorous acid and the reaction of myelo-
peroxidase with hydrogen peroxide) can lead to the for-
mation of nitrotyrosine [81]. Therefore, increased nitro-
tyrosine staining is now considered to act as an indicator
of “increased nitrosative stress” rather than a specific
marker of the generation of peroxynitrite. Respective in
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vivo and in vitro studies have demonstrated that forma-
tion of peroxynitrite contributes to the pathophysiology
of both renal I/R and hypoxia-reoxygenation injury, re-
spectively [25, 26]. Several studies have now demon-
strated that reduction of the generation of peroxynitrite
(e.g., by reduction of nitric oxide and superoxide levels)
or the presence of peroxynitrite (e.g., using the peroxyni-
trite scavenger ebselen) can produce beneficial effects
against renal I/R injury [25, 27]. We report here that
tyrphostin AG126 reduces staining for nitrotyrosine resi-
dues in kidneys subjected to I/R injury and thus, reduces
nitrosative stress. This is likely to be mediated by a reduc-
tion in nitric oxide levels subsequent to a reduction in
expression of iNOS due to inhibition of the activation
of NF-B by tyrphostin AG126.
Peroxynitrite produces cellular injury and necrosis via
several mechanisms, including peroxidation of mem-
brane lipids, protein denaturation, and DNA damage
[82–84]. Strand breaks in DNA triggers energy-consum-
ing DNA repair mechanisms and activates the nuclear
enzyme PARP, resulting in the depletion of its substrate
NAD and a subsequent reduction in the rate of glycoly-
sis [82–84]. As NAD functions as a cofactor in glycolysis
and the tricarboxylic acid cycle, NAD depletion leads
to a rapid fall in intracellular ATP. This process has been
termed the “PARP Suicide Hypothesis” [82–84]. There
is recent evidence that the activation of PARP may also
play an important role in renal I/R and the development
of ARF and that inhibition of PARP activity is beneficial
against renal I/R injury [29, 30, 85]. We demonstrate
here that tyrphostin AG126 attenuates the increase in
PARP activity caused by renal I/R. This is also likely to
be have been mediated by a reduction in peroxynitrite
levels subsequent to inhibition of the activation of NF-B
by tyrphostin AG126 followed by a reduction in nitric
oxide levels subsequent to a reduction in the expression
of iNOS.
Phosphorylation of proteins on tyrosine residues by
protein tyrosine kinases plays an important role in the
regulation of cell proliferation, cell differentiation, and
signaling processes in cells of the immune system [33, 34].
The receptor tyrosine kinases participate in transmem-
brane signaling, whereas the intracellular tyrosine ki-
nases take part in the signal transduction to the nucleus
[33, 34]. Enhanced activity of tyrosine kinases has been
implicated in the pathophysiology of many diseases [35]
and there is now good evidence that an increase in tyro-
sine kinase activity (secondary to genomic rearrange-
ments, point mutations in-frame deletions or insertions,
overexpression, and ectopic or unscheduled expression
of growth factors) plays a pivotal role in cancer growth
(e.g., chronic myeloid leukemia as well as certain solid
tumors) [36, 42]. In addition to cancer, the excessive acti-
vation of tyrosine kinase is common in conditions associ-
ated with local inflammation (e.g., rheumatoid arthritis,
atherosclerosis, psoriasis, diabetic retinopathy) or sys-
temic inflammation (e.g., sepsis and septic shock) [35, 42].
Thus, it is not surprising that the identification and the
development of novel therapeutic approaches for disease
states linked to an enhanced activation of tyrosine kinase
has become a major goal for scientists in both academia
and in the pharmaceutical industry. In the past few years,
more than 30 tyrosine kinase inhibitors have entered
preclinical and clinical development and several ATP
site–directed tyrosine kinase inhibitors are now in ad-
vances stages of clinical trials. Most notably, some of
these small molecule tyrosine kinase-inhibitors (GleevecTM,
IressaTM, TarcevaTM) have already been approved for the
use in patients with chronic myeloid leukemia [42]. The
isoflavone genistein or specific tyrphostins (AG126,
AG490, AG556, AG1641, or A1) have been used to
inhibit the activity of tyrosine kinase in animal models
of disease. Genistein inhibits a wide range of tyrosine
kinases by acting as a competitive inhibitor of the binding
of ATP and as a noncompetitive inhibitor of the sub-
strate binding to tyrosine kinase [33]. The tyrphostins,
on the other hand, act as competitive inhibitors of the
substrate binding to tyrosine kinase [35]. To date, al-
though there has only been one study demonstrating the
beneficial action of AG556 against myocardial I/R [86],
we report here for the first time, the reduction of renal
I/R injury by the tyrosine kinase inhibitor tyrphostin
AG126.
The recent sequencing of the human genome revealed
that the kinome contains 500 human protein kinase
genes, of which more than 90 are tyrosine kinases. Thus,
it is not surprising that the identification of a single agent
that specifically targets a single kinase out of the whole
human kinome has thus remained elusive. Thus, it is
possible that the beneficial effects arising from the inhibi-
tion of a specific tyrosine kinase (or a group of tyrosine
kinases) is offset by side-effects arising from the inhibi-
tion of other tyrosine kinases. As there is little informa-
tion about the specificity and selectivity (toward different
tyrosine kinases) of tyrphostin AG126 (or other tyrphos-
tins), it is difficult to point out which of the many known
tyrosine kinases play a crucial role in the pathophysiol-
ogy of I/R injury. For example, although tyrphostin
AG126 has been shown to inhibit the mitogen-activated
protein (MAP) kinase p42 (ERK2), it is also possible
that tyrphostin AG126 attenuates the activation of the
p38 MAP kinase pathway, which is known to play an
important role in the development of renal I/R injury
[87]. Further studies aimed at elucidating which tyrosine
kinase(s) is/are inhibited by tyrphostin AG126 are war-
ranted. Nevertheless, our results support the view that
inhibitors of (some) tyrosine kinases (including tyrphos-
tin AG126) may be useful in the therapy of renal I/R
injury.
Thus, in the present study we demonstrated for the first
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time that the protein tyrosine kinase inhibitor tyrphostin
AG126 reduces renal dysfunction and injury caused by
renal I/R. The mechanisms by which tyrphostin AG126
provides these beneficial effects have still to be clearly
defined but in this study we demonstrate that tyrphostin
AG126 reduces the expression of iNOS and nitric oxide
production and the renal expression of COX-2. We pro-
pose that tyrphostin AG126 reduces the activation of
the transcription factor NF-B, thereby reducing the ex-
pression of proinflammatory genes. Furthermore, we
demonstrate here that tyrphostin AG126 reduces perox-
ynitrite formation and PARP activation, both of which
are associated with the development of renal I/R injury.
The data presented here suggest that clinical studies
could be considered for the evaluation of the therapeutic
potential of tyrphostin AG126 (or similar agents) in im-
proving the course of ischemic ARF.
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